The introduction of selective serotonin (5-HT) reuptake inhibitors (SSRIs) has significantly improved the pharmacological treatment of a range of psychiatric disorders. Nevertheless, despite the undoubted advantages of antidepressant treatment in terms of improved tolerability to therapy while maintaining a high level of efficacy, not all patients benefit from it; an appreciable proportion do not respond adequately, while others may show adverse reactions. The necessary change of the initial treatment choice often requires extended periods for the remission of symptomatology. Such difficulties could be avoided if it should be possible to determine more quickly the most suitable drug. Several factors have been thought to influence the outcome of antidepressant therapy. Among the factors influencing the interindividual variability in response to treatment with SSRI, differences in genetic features may play a significant role. Several genetic polymorphisms have been associated with therapeutic SSRI response, including genetic variants of the 5-HT transporter, 5-HT-2A-receptor, tryptophan hydroxylase, brain-derived neurotrophic factor, G-protein beta3 subunit, interleukin-1beta and angiotensin-converting enzyme, although with conflicting results; also cytochrome P450 drug-metabolising enzymes may bear a particular importance, although further corroboration of the findings is necessary, and further key participating genes remain to be identified. The hope is that the identification of these genetic components will eventually facilitate the development of a customised SSRI treatment. 1 These drugs show high efficacy, and relatively few adverse reactions compared with the previously used tricyclic antidepressants, even though their mechanism of action is not entirely understood yet. However, these drugs are effective in only about two-thirds of depressed patients.
INTRODUCTION
During the last decade selective serotonin (5-HT) reuptake inhibitors (SSRIs) have revolutionised the treatment of depression, the most prevalent psychiatric disorder. 1 These drugs show high efficacy, and relatively few adverse reactions compared with the previously used tricyclic antidepressants, even though their mechanism of action is not entirely understood yet. However, these drugs are effective in only about two-thirds of depressed patients. 2 The necessary change of the initial treatment choice often requires extended periods for the remission of symptomatology. Such difficulties could be avoided if it would be possible to determine more quickly the most suitable drug for each subject. Several factors have been thought to influence the outcome of antidepressant therapy and efficient clinical predictors have not been yet identified, but there is some evidence suggesting that genetic factors play a substantial role.
Polymorphisms of drug target genes, reflected in the protein amino-acid sequence, could influence drug responsiveness. In other instances, protein expression level, or tissue distribution, could be affected by polymorphisms in a gene promoter, influencing its transcriptional control. Genes coding for proteins somewhat involved in monoaminergic pathways and other possible targets of antidepressant action could present functional polymorphisms, altering their constitutive activity, and furthermore, many of the drug-metabolising genes exhibit functional polymorphism that contributes to the interindividual variability in drug efficacy and toxicity. For example, the polymorphic cytochrome P450 (CYP) CYP2D6 metabolises several drugs implicated in common toxic reactions in individuals with low enzyme activity, such as tricyclic antidepressants. Collectively, these aspects of drug response variability belong to the emerging field of pharmacogenomics. 7 Pharmacogenomics is the study of how an individual's genetic inheritance affects the body's response to drugs: it examines how genetic makeup affects this response. Pharmacogenomics combines traditional pharmaceutical sciences, such as biochemistry, with annotated knowledge of genes, proteins, and single-nucleotide polymorphisms (SNPs). Some authors had differentiated it from pharmacogenetics: the former should refer to the general study of all of the many different genes that determine drug behaviour, while the latter should refer to the study of inherited differences (variations) in drug metabolism and response. For other authors, pharmacogenetics is more focused in scope than pharmacogenomics, which would encompass factors beyond those that are inherited, and is viewed as a subset of it. For other authors, the distinction between the two terms is considered arbitrary and the two terms could be used interchangeably.
The emerging field of pharmacogenetics/pharmacogenomics holds great potential, particularly in psychiatry, for refining psychopharmacology, given the lack of biologically based treatment guidelines. [8] [9] [10] This field gained increasing attention and holds great promise for clinical medicine in the latest years. [11] [12] [13] [14] A major obstacle to the advance of pharmacogenomics is the difficulty in finding candidate polymorphisms. SNPs, in fact, occur every 1000 bases; therefore, millions of SNPs must be identified and analysed to determine their involvement (if any) in drug response. Further complicating the process is our limited knowledge of which genes are involved with each drug response. Since many genes are likely to influence responses, obtaining the big picture on the impact of gene variations is highly timeconsuming and complicated. For this reason, candidate genes should be chosen according to their possible implications with pharmacological action and pathogenic mechanisms.
The foremost theory for explaining the biological basis of antidepressant action is their ability to improve monoaminergic transmission. Antidepressant drugs are therefore classified according to their properties in improving monoaminergic transmission in the different biogenic monoamine systems: 5-HT, noradrenaline (NA), and dopamine (DA). Since this first theory, other explanations based on the ability of antidepressants to act on the abnormal function of monoamine receptors or some impaired signalling pathways have been suggested. Behavioural, electrophysiological, and microdialysis studies have shown that 5-HT receptors, mainly 5-HT1A, 5-HT1B, and 5-HT2C subtypes, exert a key role in modulating antidepressant activity. Indirect activation of neurotransmitter receptors by antidepressants may also lead, via increases in endogenous levels of 5-HT in synapses in specific brain regions to the activation of various G protein-coupled receptors, signal transduction, transcription factors, and neurotrophic factors such as brain-derived neurotrophic factor. These hypotheses need to be clarified by molecular biology. 15 Pharmacogenetic studies in mood disorder were performed only in recent years for a review see Serretti et al. 16 Polymorphisms of some genes have been studied to date to test their association with antidepressant response. The choice of candidate genes has taken into account the possible involvement of each gene in the pathophysiology of the disease and in the mechanism of action of the analysed drugs.
CANDIDATE GENES Tryptophan Hydroxylase (TPH)
The TPH gene, which codes for the rate-limiting enzyme of 5-HT biosynthesis, has been cloned 17 and mapped on 11p15.3-p14. 18 Studies on the administration of N-ethyl-3,4-methylenedioxyamphetamine to rats showed a significant concentration decline of 5-HT and of TPH activity in the hippocampus. 19 In addition, long-term treatment of rats with sertraline has been shown to upregulate mRNA and protein levels of TPH, as determined by in situ hybridisation and immunocytochemistry, respectively. 20 These findings suggest a crucial role of TPH in pharmacological action of AD.
The best known TPH variants are the two biallelic polymorphisms in strong disequilibrium on position 218 (A218C) and 779 (A779C) of intron 7. 21 The polymorphism A218C is located in a potential GATA transcription factorbinding site, so that it may influence gene expression, and consequently the antidepressant response. The rarer TPH*A of A218C allele was shown, in fact, to be associated to a decreased 5-HT synthesis. 22 Our group published two pharmacogenetic studies on A218C polymorphism. The first study involved a sample of major and bipolar depressives, with or without psychotic features. In all, 217 inpatients were treated with fluvoxamine 300 mg and either placebo or pindolol in a doubleblind design for 6 weeks, assessing the severity of depressive symptoms weekly with the Hamilton Rating Scale for Depression. TPH allelic variants were determined in each subject by using a PCR-based technique. No significant finding was observed in the overall sample as well as in the pindolol group, while TPH*A/A was associated with a slower response to fluvoxamine treatment in subjects not taking Pharmacogenomics of SSRIs pindolol (P ¼ 0.001). 23 The other study was performed on a sample of 121 inpatients with a major depressive episode treated with paroxetine 20-40 mg with either placebo or pindolol in a double-blind design for 4 weeks. TPH*A/A and TPH*A/C variants were associated with a poorer response to paroxetine treatment when compared to TPH*C/C (P ¼ 0.005); this difference was not present in the pindolol augmented group. Other variables, such as sex, diagnosis, presence of psychotic features, severity of depressive symptomatology at baseline and paroxetine plasma level, were not associated with the outcome. 24 Recently, the same polymorphism was investigated with monoamine oxidase A (MAOA)-variable number tandem repeat (VNTR) in 66 Japanese patients with a major depressive disorder during a 6-week controlled study. Only 54 patients completed the study, and they failed to demonstrate the association of the two polymorphisms with the antidepressant effect of fluvoxamine; 25 however, it must be observed that the sample was smaller than those of the previous studies and belonging to a different ethnicity. The same Japanese group also published a paper reporting the lack of association between this and other polymorphisms with the development of fluvoxamine-induced nausea. 26 Recently, a second gene encoding TPH was described for vertebrates, called TPH2. 27 By gene targeting, the same authors ablated this gene in mice. The resulting animals exhibited close to normal levels of 5-HT in the brain stem, where this gene is predominantly expressed, while the classical TPH gene, now called TPH1, is expressed in the gut, pineal gland, spleen, and thymus. These findings lead to a new concept of the 5-HT system, with the presence of two 5-HT systems in vertebrates, independently regulated and with distinct functions. 28 In the light of these recent findings, pharmacogenetic studies on TPH1 should be reconsidered; positive findings in association study could be explained with the presence of an involvement of the 'peripheral' 5-HT system in pharmacological antidepressant response or with the presence of a polymorphic gene in strict linkage disequilibrium with TPH1 gene, which could be the actual gene associated with a better response to antidepressants.
Monoamine Oxidase
The catabolism of catecholamines is catalysed by catechol-O-methyltransferase (COMT), and monoamine oxidaseA, which catalyses also 5-HT catabolism. 29 These enzymes, being involved in the elimination of biogenic amines from the synaptic cleft, could also be involved in the different individual response to ADs, as potentially impaired variants could be more constitutionally active in amine catabolism, contrasting the action of ADs. In addition, MAOA is the specific target of the first synthesised ADs, MAO inhibitors (MAOI).
MAO-A gene is located on Xp11.23. 30 A polymorphism located 1.2 kb upstream of the MAO-A coding sequences has been shown to affect the transcription of the MAO-A gene promoter. This mutation consists of a 30 bp repeat in 3, 3.5, 4 or 5 copies, The polymorphism was shown to affect transcriptional activity of the MAOA gene promoter. 30, 31 A pharmacogenetic study on moclobemide response 32 found no association between AD response and the variants at the polymorphism in the promoter of MAO-A gene. A recent study found no association between the same polymorphism and AD response to fluvoxamine in a Japanese sample. 25 Our group tested the association between fluvoxamine and paroxetine efficacy in a sample of 248 unipolar and 195 bipolar depressed patients, with or without psychotic features. 307 inpatients were treated with 300 mg fluvoxamine and 136 with 20-40 mg paroxetine for 6 weeks. The severity of depressive symptoms was assessed weekly with the HAMD and allele variants were determined by a PCR-based technique. We observed no association between MAOA genotypes and antidepressant response.
33
Beta1 Adrenergic Receptor Beta adrenergic receptors, which are only postsynaptic, stimulate the formation of cAMP after the linkage of the agonists to the receptor. Beta1 and beta2 adrenergic receptors (ADRB1-ADRB2) are coupled to G protein.
ADRB1 serve as important regulators of central nervous system (CNS)-mediated behaviour and several neural functions, including mood, memory, neuroendocrine control, and stimulation of autonomic function. ADRB1 5 0 -flanking region contains AP-2 consensus elements that can interact with transactivating elements. 34 Studies on the action of antidepressants suggest that they may play a critical role in affective disorders and their treatment; centrally active beta1 and beta2 adrenergic agonists produce antidepressant-like effects in several behavioural tests, suggesting that these receptors may be involved in the mediation of the effects of antidepressant drugs; 35 ADRB1 and ADRB2 stimulate the accumulation of cyclic AMP, probably with two independent mechanisms of action.
ADRB1 was mapped on 10q24-q26. 36 At nucleotide 1165, a guanine (wild-type) or cytosine variant was found leading to the amino-acid variation Gly389Arg, which is located in the intracellular cytoplasmatic tail near the seventh transmembrane-spanning segment. This variant of the human ADRB1 gene results in alterations of receptor-Gs protein interaction, with functional consequences on signal transduction. 37 The C allele of these polymorphisms is associated with an enhanced coupling to the stimulatory Gs protein and increased adenylyl cyclase activation, disturbances, often observed in affective disorders. This polymorphism, located in a putative G-protein binding domain, might thus influence the therapeutic response in major depression. It was investigated for association with a major depression or with the response to antidepressant treatment in a sample of 259 patients compared to 206 healthy controls. A tendency for a relation between CC homozygosity and a better and even faster response to various antidepressant treatments was found, determined by the HAMD and clinical global impression (CGI) score (P ¼ 0.05). The patients were treated with tricyclic antidepressants, noradrenergic-and Pharmacogenomics of SSRIs A Serretti and P Artioli serotonergic-specific agents, selective norepinephrine reuptake inhibitors. Even though after correction for multiple testing (Bonferroni), these results did not remain significant, these findings suggest that the presence of the C allele might be an indicator for antidepressant treatment response.
DOPAMINERGIC RECEPTORS
The potentiation of DA transmission by antidepressant treatments, as revealed by the increased motor stimulant response to DA agonists in experiment animals, takes place after 2-3 weeks of treatment, and it is still present 3 days, but not 10 days after treatment discontinuation. Antidepressant treatments were shown to enhance dopaminergic neurotransmission by increasing the behavioural sensitivity to the stimulation of DA receptors in the mesolimbic DA system, and such super sensitivity might underlie the antidepressant therapeutic effect. 38 The only AD that ignores the 5-HT system and acts exclusively on dopaminergic and adrenergic systems is bupropion 39 even though this finding was recently criticised. 40 At least five different DA receptors were identified: D1, D2, D3, D4, and D5/D1b. DA receptor D2 (DRD2) was mapped on 11q23. 41 This G-protein-coupled receptor inhibits adenylyl cyclase activity. DRD2 seems to exert a central role in the neuromodulation of appetitive behaviours, as DRD2 knockout mice show a total suppression of rewarding behaviour with morphine, with normal responses when food was used as a reward. 41, 42 Itokawa et al 43 reported a putatively functional polymorphism causing a structural change from serine to cysteine at codon 311 of DRD2 (S311C). The signal transducing action of the DRD2 receptor following ligand binding is to inhibit cAMP synthesis and the Cys311 variant is less effective in inhibiting it.
DRD4 showed considerable homology to DRD2 and to DRD3. Rubinstein et al 44 proposed that DRD4 modulates normal, coordinated, and drug-stimulated motor behaviours as well as the activity of nigrostriatal DA neurons. DA D4 receptor activation was shown to inhibit presynaptically glutamatergic neurotransmission in the rat supraoptic nucleus. 45 DRD4 was mapped on chromosome 11p15.5; it is one of the most variable human genes known. Most of this diversity is the result of length and SNP variation in a 48-bp VNTR in exon 3, 46 which encodes the third intracellular loop of this DA receptor. Variant alleles containing 2 (2R) to 11 (11R) repeats are found, with the resulting proteins having 32 to 176 amino acids at this position. The frequency of these alleles varies widely, the four-fold repeat (D4.4) being most frequent.
Concerning dopaminergic receptors, our group investigated the possible association of the DRD2 (Ser 311Cys) and DRD4 exon 3 VNTR gene variants with the antidepressant activity of SSRIs. The sample consisted of 266 depressed inpatients treated with fluvoxamine 300 mg/day, and 98 treated with paroxetine 20-40 mg/day. The severity of depressive symptoms was assessed weekly with the Hamilton Rating Scale for depression. DRD2 and DRD4 allelic resulted not associated with response to treatments. Possible stratification factors, such as sex, diagnosis, presence of psychotic features, depressive symptoms at baseline, paroxetine and fluvoxamine plasma levels, and pindolol augmentation, did not significantly influence the negative results. 47 SEROTONERGIC RECEPTORS 5-HT is found in neuronal cell bodies clustered specifically in the brainstem. The axons of these cells, however, innervate almost every area of the CNS. Beside its fundamental role in mood tone, 5-HT is also involved in eating, sleeping, sexual behaviour, the circadian cycle, and other neuroendocrine functions. In addition, the serotonergic pathway is the main target of SSRIs, the most widely used antidepressant compounds.
There are multiple subtypes of 5-HT receptors, with varying affinity. They are categorised into seven main classes (5-HT1-7).
5-HT2A gene was mapped on chromosome 13q14-q21; 48 it consists of three exons separated by two introns and spans over 20 kb. When the 5-HT2A receptor is stimulated by 5-HT, it causes the production of second messengers, modulating phosphatidylinositol production and intracellular Ca 2 þ flux. The activation of 5-HT2A receptors of the medial prefrontal cortex and anterior cingulate cortex is thought to mediate the hallucinogenic properties of LSD, whereas in amygdala 5-HT2A receptor activation is a component of the response. The 5-HT2A receptors may mediate some of the antidepressant effects seen in experimental animal models of depression. 49 Nefazodone exerted its antidepressant effects partially through 5-HT2A receptor antagonism. 50 A polymorphism in the promoter region was identified (A-1438G), which creates an HpaII restriction site 51 and associated to clozapine response. 52 A silent polymorphism T102C was identified by Warren et al 53 and was associated to individual responses to risperidone 54 and clozapine. 55 A study was performed to investigate whether À1438G/A polymorphism in the promoter region of the 5-HT2A receptor gene was associated with therapeutic response to fluvoxamine in 66 Japanese patients with a major depressive disorder. Of these, 55 patients completed the study, and the genotype distribution and the allele frequencies showed no significant differences between responders and nonresponders. The time course of the Montgomery-Asberg Depression Rating Scale scores showed no significant differences among À1438G/G, À1438G/A, and À1438A/A genotype groups. 56 Our group tested the effect of 5-HT2A gene T102C variants on the antidepressant activity of fluvoxamine and paroxetine in the same sample of MAOA study (248 major and 195 bipolar depressed patients, with or without psychotic features, see above), and we observed a marginal association between 5-HT2A variants and antidepressant response. 33 Another paper, besides investigating association between T102C polymorphism and major depression, tested the Pharmacogenomics of SSRIs association with antidepressant treatment response in a subsample of patients; the treatments were nonstandardised and the subsample size was exiguous, but they find an association between good response (calculated as a decrease in HAMD 17 and CGI item 1) and the presence of C allele. 57 5-HT6 receptor is G protein coupled and stimulates adenylyl cyclase. In the rat, it shows high affinity for several therapeutically important antidepressant such as mianserin and clomipramine and antipsychotic drugs, particularly the atypical antipsychotics such as clozapine. A mutant receptor in which serine 267 in the C-terminal region of the third intracellular loop was changed to lysine shows 10-fold higher affinity for 5-HT than the native receptor and demonstrates agonist-independent activity; clozapine decreased the basal activity of this mutated receptor to vector control levels.
Kohen et al 58 cloned and characterised the human 5-HT 5-HT6 receptor gene, which encodes a 440 amino-acid polypeptide and mapped to human chromosome 1p36-p35, not far from the location of the 5-HT1D alpha receptor. They showed that the receptor is expressed in several human brain regions, most prominently in the caudate nucleus. Study of genomic clones revealed that the open-reading frame is interrupted by two introns in positions corresponding to the third cytoplasmic loop and the third extracellular loop, respectively. 5-HT6 receptor antagonists seem to improve retention performance and behavioural studies on animals implicated a role for 5-HT6 in cognition enhancement: this has been supported by in vivo microdialysis studies that showed how a selective 5-HT6 antagonist produces an increase in extracellular glutamate levels in the frontal cortex.
A silent thymidine to cytosine polymorphism at position 267 (TC 267), within the first exon of HTR6, has been identified. 58 This genetic polymorphism was investigated for association with antidepressant response in 34 major depressive disorder patients completing a 4-week treatment with various antidepressants, administered at not fixed doses, and assessed with the HAMD before antidepressant treatment and at the end of the trial. The results provide a lack of association between C267T genetic variants and antidepressant response for these patients. 59 Serotonin Transporter (SERT) The brain SERT appears to be a principal site of action of many antidepressants and may mediate behavioural and toxic effects of cocaine and amphetamines. Its role is to take up 5-HT into the presynaptic neuron, which thus terminates the synaptic actions and recycles it into the neurotransmitter pool.
Ramamoorthy et al 60 identified and cloned a single gene encoding the human SERT, localised to chromosome 17q11.1-q12. The gene spans 31 kb and consists of 14 exons. 61 64 called it 5-HTTLPR and studying lymphoblastoid cell lines found that the basal activity of the long variant was more than twice that of the short form of the SERT gene promoter.
Our group performed several studies on SERTPR (the new name of 5-HTTLPR polymorphism), the first paper being published in 1998. We tested the hypothesis that allelic variation of the SERT promoter could be related to the antidepressant response to fluvoxamine and/or augmentation with pindolol. In all, 102 inpatients with a major depression with psychotic features were randomly assigned to treatment with fluvoxamine and either placebo or pindolol for 6 weeks. Depression severity was assessed weekly with HAMD, and allelic variations were detected by a PCR-based method. Both homozygotes for the long variant (l/l) and heterozygous (l/s) showed a better response to fluvoxamine than homozygotes for the short variant (s/s). In the group treated with fluvoxamine plus pindolol, all the genotypes acted like l/l treated with fluvoxamine alone. 65 A following study analysed a wider sample of major and bipolar depressives, with or without psychotic features, composed of 155 inpatients treated in the same standardised method of the previous study, and carrying out the same assessment of the antidepressant outcome. Also in this study SERTPR s* allele was associated with a poor response to fluvoxamine treatment, and the diagnosis, the presence of psychotic features, and the severity of depressive symptomatology did not influence the association. 66 In a third study, we investigated the persistence of the finding for another antidepressant treatment, analysing the association of alleles at SERTPR polymorphism with paroxetine treatment and evidencing an analogue finding. 67 The s* allele was in fact associated with a less favourable and slower response, and the finding was independently replicated by Pollock et al, 68 who examined 95 elderly patients receiving paroxetine or nortriptyline in a standardised treatment. Patients were treated for up to 12 weeks and assessed weekly with clinical ratings and measurements of plasma drug concentrations; they found a significantly more rapid mean reductions from baseline in HAMD for patients with the l/l genotype, despite equivalent paroxetine concentrations. Similar findings were obtained with citalopram, in a Spanish sample. 69 More recently, a study examined the treatment outcome with fluoxetine (1.25-40 mg/day) in 51 patients with a major depression, searching for association with SERTPR alleles and measuring also platelet SERT kinetics before treatment. The researchers hypothesised the possibility that one genotype could express a lower-dose fluoxetine response. After a 1-week placebo lead-in, the 24-item Hamilton depression rating stale was administered, and repeated after 6, 12, and 18 weeks of treatment. A repeatedmeasures analysis of variance of 24-item Hamilton depression change through baseline was performed to test a genotype effect on the outcome. Genotype as well as affinity Pharmacogenomics of SSRIs constant and dose show a significant effect on the outcome. SERTPR seemed to show both a placebo response effect and a drug dose response effect: in fact, the l allele group was more responsive to placebo as well as more responsive to drug dose than the s allele group. Of course, the small size of the sample does not allow any definite conclusion. 70 Studies performed in an Asian population showed contrasting results: Kim et al 71 found an association in the opposite direction, as in their sample homozygotes subjects for the s allele showed a better response both to fluvoxamine and to paroxetine. Two subsequent studies confirmed this result in Asian populations: one analysed 66 Japanese patients with a major depressive disorder in a 6-week study with fluvoxamine; the short allele frequency was significantly higher in responsive individuals than in nonresponsive ones. 72 Conversely, the second study on 121 Chinese patients diagnosed with a major depression revealed that patients with the l/l genotype had a significantly better response to fluoxetine, as evaluated on the basis of total, core, psychic-anxiety, and somatic-anxiety HAMD score percentage change, according to the results in Caucasians populations. 73 Finally, Ito et al 74 studied the association between SERTPR and response to fluvoxamine prescribed up to 200 mg/day for 6 weeks in 66 patients with a major depressive disorder, and found no significant association either for s or for l variant. In Asian population, the results are thus very conflicting, most probably the small sample sizes, different ethnicity and different definition of responders do not allow to draw a definite conclusion on the role of the SERTPR polymorphism.
In a recent study, the presence of s allele was also associated to antidepressant-induced mania, 75 even though this finding was not confirmed in our data. 76 Nitric Oxide Synthase (NOS) Nitric Oxide (NO) is probably involved in the processes of learning and memory, as it influences synaptic plasticity in the striatum and elsewhere. NO is produced from its precursor L-arginine by the enzyme NOS, which includes at least three distinct isoforms-neuronal (NOS1), endothelial, and inducible NOS. The neuronal but so far not the endothelial NOS isoform (NOS3) was detected in some striatal interneurons with a large axonal arborisation. On the other hand, in the hippocampus, NOS1 is localised to GABAergic interneurons, whereas endothelial NOS is found in pyramidal neurons.
Recent studies have implicated NOS in the mechanism that underlies the therapeutic efficacy of antidepressant medication. 77, 78 In addition, MD patients were found to have significantly higher plasma nitrate concentrations than normal subjects, an index of NO production, in comparison to normal subjects. In addition, NOS antagonists were shown to produce antidepressant-like response. 79 The NOS1 gene was mapped to chromosome 12q24.2-q24. 31 . In a population-based association study, the NOS1 C276T polymorphism was investigated for its involvement in conferring susceptibility to MD, and its association with fluoxetine response in 114 MD patients who underwent a 4-week fluoxetine treatment. The results demonstrate the NOS1 variants to be found at similar frequencies in MD patients and healthy control subjects. Further, the variants did not influence the fluoxetine response in MD patients. 80 G-PROTEIN BETA3 SUBUNIT G proteins are key components of intracellular signal transduction in neurons and in all cells of the body. 81 They are trimers, whose function depends on the ability to dissociate into an alpha monomer bound to GTP dissociated from a beta-gamma dimmer. In the trimeric state the G protein is inactive, and it is constitutively associated with the receptor; chronic treatment with fluoxetine was shown to attenuate GTP binding to gamma subunit in the dorsal raphe nucleus of rats, thus inducing desensitisation of 5-HT1A receptors. 82 Beta subunit could be subdivided into three subtypes: 1, 2, and 3. Gbeta3 subunit (GNB3) gene was mapped on locus 12p13 and spans 7.5 kb and is composed of 11 exons and 10 introns. Its promoter lacks a TATA box but harbours GC-rich regions. A polymorphism of a G-protein beta3 subunit (C825T) has been shown to be associated with increased signal transduction and ion transport activity; 83 GNB3 825T variant is associated with the occurrence of the splice variant Gbeta3s, which, despite a deletion of 41 amino acids, is functionally active in reconstituted systems. Although the polymorphism did not affect the amino-acid sequence of the beta3 subunit, the T allele was associated with deletion of nucleotides 498-620 of exon 9; this was found to be an example of alternative splicing caused by a nucleotide change outside the splice donor and acceptor sites.
Gbeta3 polymorphism was associated with response to AD treatment in 88 depressive patients (10 bipolar disorder, 78 major depression) compared with 68 schizophrenic patients and 111 healthy controls. A significant association was found between TT homozygosity and response to various AD treatments after 4 weeks. 84 In our centre, we could replicate this finding in a sample of 490 subjects, bipolars and major depressives, treated with SSRIs fluvoxamine and paroxetine. Subjects with Gbeta3 T/T variants showed better response to treatment (P ¼ 0.009) and this effect was independent from analysed demographic and clinical variables. 85 These are to our knowledge the first studies investigating association between a polymorphism in a molecule involved in intracellular signal transduction pathway and AD action.
Angiotensin-Converting Enzyme (ACE)
Angiotensin I-converting enzyme, or kininase II, is a dipeptidyl carboxypeptidase that plays an important role in blood pressure regulation and electrolyte balance. Although ACE has been studied primarily in these contexts, this widely distributed enzyme has many other physiologic functions. The ACE gene encodes two isozymes. 86 Ehlers et al 87 determined the cDNA sequence for human testicular ACE, identical, from residue 37 to its C-terminus, to the second half or C-terminal domain of the endothelial ACE sequence. The inferred protein sequence consists of a Pharmacogenomics of SSRIs A Serretti and P Artioli 732-residue preprotein including a 31-residue signal peptide. Using a DNA marker at the growth hormone gene locus, which they characterised as 'extremely polymorphic' and which showed no recombination with ACE, Jeunemaitre et al 88 mapped ACE to 17q22-q24. After the ACE gene was cloned, it was shown that 50% of the interindividual variability of plasma ACE concentration is determined by an insertion (I)/deletion (D) polymorphism situation in intron 16 of the ACE gene and known as the ACE I/D polymorphism, 89 with the D allele showing dominance rather than codominance relative to the I allele. 90 ACE inhibitor has mood-elevating effects 91 and central ACE activity is increased for suicidal patients. 92 In addition, substance P (SP), which is degraded by ACE, has been implicated in the pathogenesis of depressive symptoms 93 and evaluated in the treatment for MD. 94 A study on 99 unrelated Caucasians patients with MD and 99 age-and sex-matched healthy controls from the general population, rated with the Hamilton Rating Scale for depression (HAM-D17) and the CGI scale (Item 1-severity of disease) and receiving different treatments (tricyclic antidepressants, mirtazapine, SSRIs, venlafaxine, electroconvulsive therapy, repetitive transcranial magnetic stimulation, and combinations), found that after 4 weeks of treatment, D-allele carriers showed significantly lower HAM-D17 scores, remitted more often and had a significantly shorter duration of hospitalisation. Also, the number of treatment alterations during hospitalisation was significantly higher in I/I genotypes. Thus, the D-allele might positively influence the onset of therapeutic efficacy, while homozygosity for the I-allele seems to be associated with delayed response. 95 Another recent study has tested the hypothesis that an ACE gene I/D polymorphism could be associated with antidepressant response in 58 MD patients treated with venlafaxine slow release 75 mg or fluoxetine 20 mg, not replicating the previous finding. 96 Interleukin-1 (IL-1)beta IL-1, produced mainly by blood monocytes, mediates the host reactions of acute phase response. It is identical to endogenous pyrogen. The IL-1 complex consists of three linked genes (IL-1 Alpha, IL-1beta, and IL-1 receptor antagonist) mapping to chromosome 2q13-q14. 97 All three molecules bind to IL-1 receptors. Auron et al 98 isolated human IL-1 cDNA, while Webb et al 99 assigned the IL-1 gene to chromosome 2q13-q21. IL-1beta was assigned to the end of 18q. 100 Owen et al 101 report elevated plasma concentrations of IL-1 in a major depression and postviral depression. Previously, it has been reported that the production rate of IL-1 is increased in dysthymia and major depression; [102] [103] [104] thus, increased production of IL-1 and other proinflammatory cytokines may provide a mechanism for the psychological and organic aetiologies of the disease. The acute stage of unipolar and bipolar depression is accompanied by activation of the inflammatory response system (IRS), with an increase in the number and percentage of peripheral blood leucocytes, neutrophils, and activated T cells, increased neopterin secretion in serum and urine, an increased production of prostaglandins in plasma or cerebrospinal fluid, and the presence of an acute phase response. 105 IL-1 has behavioural effects, and may induce a behavioural complex in female rats, called sickness behaviour, characterised by locomotor retardation, sleep disorders, soporific effects, anorexia, weight loss, hyperalgesia, decreased social exploration, and inhibition of sexual behaviour. 106 The mechanisms whereby IRS activation may induce depression is still not known, but it is hypothesised that modulation of the HPA axis activity, with increased corticotropin-releasing hormone secretion, and modulation of the serotonergic turnover may be involved. Several lines of evidence indicate that brain cytokines, principally IL1beta and IL-1 receptor antagonist, may have a role in the biology of a major depression, and that they might additionally be involved in the pathophysiology and somatic consequences of depression as well as in the effects of antidepressant treatment. 107 Four SNPs have been reported in the IL-1beta gene: À31C/ T (promoter), À511C/T (promoter), þ 3954C/T (exon 5), and A/G (intron 4) at position 5810. [108] [109] [110] The À31 SNP is in strong linkage disequilibrium with the À511 SNP. 111 The association of the biallelic polymorphism À511C/T, located in the promoter region of the IL-1beta gene, to fluoxetine response was studied in 119 MD patients who received a 4-week fluoxetine treatment. MD patients who were homozygous for the À511T allele of the IL-1beta gene had a trend of less severity of depressive symptoms and more favourable fluoxetine response than À511C carriers. 112 Cytochrome P450 Drug-metabolising enzymes have been recognised as a major source of pharmacokinetic variability within and between patients. Much focus has been given to genetic-based differences in the activity of certainCYP enzymes responsible for the metabolism of a wide variety of commonly used drugs, in particular, in psychiatry and for the treatment of depression. The CYP family of liver enzymes is responsible of the catabolism of at least 30 different classes of drugs. DNA variations in genes coding for these enzymes can influence their ability to metabolise certain drugs, thus causing drug overdose in patients.
The P450 enzymes have been classified according to their amino-acid homology: CYP1A, CYP2A6, CYP2B6, CYP2C, CYP2D6, CYP2E1, and CYP3A enzymes account for approximately 70% of human liver CYP.
Marked differences exist between the SSRIs with regard to their effects on specific CYP enzymes. CYP describes a class of haeme-containing proteins that represent the major enzymes responsible for the oxidation and reduction of numerous endogenous substrates and drugs. 113 For example, fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor. Fluoxetine and paroxetine are potent CYP2D6 inhibitors, whereas the main metabolite of fluoxetine, norfluoxetine, has a moderate inhibitory effect on CYP3A4. Sertraline is a Pharmacogenomics of SSRIs moderate CYP2D6 inhibitor; only citalopram appears to have little effect on the major CYP isoforms. Fluoxetine deserves special attention as inhibitory effects on CYP activity can persist for several weeks after fluoxetine discontinuation because of the long half-life of fluoxetine and its metabolite norfluoxetine. 114 Application of molecular genetic techniques resulted in the cloning of a complementary DNA (cDNA) and the gene Also CYP2C19 show genetic polymorphisms and the differences in phenotype between people carrying the different isoforms allowed to make a distinction between individuals with a normal catalytic function, the so-called extensive metabolisers, and a group of individuals with a severely impaired catalytic capacity, so-called poor metabolises (PM). 115, 116 The CYP2D6 PM phenotype occurs at a frequency of approximately 5-10% in the Caucasian population, while it is much rarer in Black Americans and in Orientals. On the other hand, the frequency of the CYP2C19 PM phenotype observed in Orientals is about 20%, while in Caucasians it reaches only 2-5%. 115, 116 As previously said, CYP2D6 is inhibited in order of decreasing potency by SSRIs paroxetine, norfluoxetine, fluoxetine, sertraline, fluvoxamine, and citalopram. For paroxetine and fluoxetine, however, plasma concentrations and dosage strongly influence the magnitude of enzyme inhibition. In contrast, no significant correlations emerged between CYP2D6 inhibition and plasma concentrations of sertraline or fluvoxamine. The potential of paroxetine as an inhibitor may be affected by the genotypes and metabolic capacities of individual subjects. 117 Furthermore, fluoxetine, sertraline, and paroxetine have a persistent effect on CYP2D6 following drug discontinuation. 118 Both PM 119 and UM 120 have been reported at increased rates in selected populations such as depressive inpatients. This is possibly due to the concentration of difficult cases in a tertiary-care setting, thus implying the clinical importance of the polymorphisms. 121 Owing to the large number of patients necessary, only few studies with limited power directly assessing the question of possible association between these polymorphisms and antidepressant response are available. 122 They indicate more predictive power for the avoidance of adverse drug reactions rather than clinical efficacy. No study analysing the possible influence on SSRI response is, to our knowledge, yet available (Table 1) .
PERSPECTIVES
The frequently reported statement that it will soon be possible to individualise and tailor the choice and dosing of pharmacotherapy, not only for depressive illness, is an idealistic view at present, and further investigation is required. This type of research is important for its actual clinical significance and the benefits that can be obtained from genotyping for polymorphisms related to pharmacokinetics and pharmacodynamics. Considering the major clinical and economic importance of individual drug response, this field of research deserves major attention, not only by specialists but also by primary-care physicians, health officials, and the health industry.
The introduction of new technologies, such as DNA microarray (DNA chip) analysis, represents a further chance to implement and make use of genetic information available in everyday clinical practice. In fact, it enables quick genome-wide scanning, using the high-density SNP map. This procedure, however, shows substantial limitations. Although microarray-related studies can monitor global changes in gene expression, these studies are limited by access and cost; moreover, a simultaneous analysis of thousands of genes, many of which are nonfunctional or not related with the trait under analysis, leads to a risk of false-positive findings.
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